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1. ABSTRACT 
 
AIM: Oxaliplatin is a third-generation platinum-based chemotherapy 
drug, introduced for management of the advanced stages of metastatic 
colorectal cancer. However, repeated administration of oxaliplatin 
induced acute and chronic peripheral neuropathy. Valproic acid (VPA) 
is a neurotherapeutic drug used widespread and worldwide as therapy 
for seizures, bipolar disorder, and migraine, including children, adult 
and women of reproductive age.  
MATERIALS AND METHODS: In the present study, we investigated 
the effect of VPA in prevention of oxaliplatin-induced periphery 
neuropathy in the rat model. We demonstrated that VPA (300 mg/kg) 
relieved the oxaliplatin (4mg/kg)-induced peripheral neuropathy using 
behavioral tests, biochemical tests, and histopathological and 
immunohistochemical evaluations.  
RESULTS: VPA administration significantly attenuated the mechanical 
hyperalgesia by oxaliplatin-induced in rats. VPA exerted a significant 
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protective effect by reducing the occurrence of multinucleolated 
neurons and the nucleolar eccentricity caused on lumbar dorsal root 
ganglion from oxaliplatin-treated rats. It revealed an inhibitory effect 
of VPA on the number and activation of microglia and astrocytes in the 
dorsal horn of the spinal cord. However, VPA was unable to prevent 
demyelination and degeneration of nerve fibers from oxaliplatin-
induced peripheral neurotoxicity.  
COLUSION: The present results demonstrated for the first time that 
VPA administration ameliorated the oxaliplatin-induced behavioral, 
biochemical and histopathological changes in rats. The VPA-mediated 
effects in this study may be attributed to neuroprotection properties 
and ameliorating oxaliplatin-induced astrocytes and microglial 
activation. VPA may offer a dual protective approach against etiological 
factors and resulting maladaptative plasticity. 
Keywords: Oxaliplatin, Peripheral neuropathy, Mechanical allodynia, 
Valproic acid, Astrocyte and Microglia, Nucleolar eccentricity 
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2. INTRODUCTION 
 
Oxaliplatin is a third-generation platinum-based chemotherapy drug 
in various solid tumours, in particular, it was introduced for the 
management of the advanced stages of metastatic colorectal cancer 
[1]. However, it has been reported that repeated administration of 
oxaliplatin induced severe acute and chronic peripheral neuropathy [2]. 
Oxaliplatin induced neuropathy can persist from months to years 
beyond chemotherapy completion, causing significant challenges for 
cancer survivors due to negative influence on function and quality of 
life. Oxaliplatin neurotoxicity resulted in chemotherapy dose reductions 
or early discontinuation [3]. 
Acute neuropathy shows cold hyperalgesia in the early phase and 
includes acral paresthesias enhanced by exposure to cold in 71 to 95% 
of all patients [4,5]. It has been thought that the acute neuropathy is 
not due to morphological damage of the nerve [6] and is due to 
alternations of voltage-gated Ca2+ and K+ channels [7]. On the other 
hand, the dose-limiting toxicity of this compound is the development 
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of peripheral neuropathy with glove-and-stocking distribution sensory 
loss, combined with paresthesia, dysesthesia, pain, and motor 
neuropathy [3,6,8]. A chronic neurological syndrome, related to the 
total cumulative dose as well as the dose-intensity of treatment 
persists between and after treatments [9] negatively influencing 
patient’s quality of life. Thus, these neuropathies are a major clinical 
problem in oxaliplatin chemotherapy.  
To ameliorate oxaliplatin-induced neuropathy, various treatments by 
animal experiments have been suggested including gabapentin [10], 
neurotropin [6], carbamazepine [11], phosphatidylcholine [12], N-
palmitoylethanolamine [3], exenatide [8], and goshajinkigan [2]. 
There is no currently univocally-accepted proven therapy for 
oxaliplatin-induced neuropathy. Most randomized controlled trials 
testing a variety of drugs with diverse mechanisms of action failed to 
reveal an effective treatment. Recently, most reports including 
glutathione [13], duloxetine [14], Vitamin E [15], oxycodone [16], 
goshajinkigan [17], pregabalin [18] and MR309 (a novel selective 
sigma-1 receptor ligand previously developed as E-52862) [19] show 
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some effects. Neuroprotective, safe, preventive agents as adjuvant to 
chemotherapy are a therapeutic need.  
Valproic acid (VPA) is a neurotherapeutic drug prescribed worldwide 
as therapy for seizures, bipolar disorder, and migraine, including 
children, adult and women of reproductive age. It is one of the major 
antiepileptic drugs in clinical practice and the drug of choice par 
excellence for all varieties of generalised epilepsy syndromes, primary 
or symptomatic [20]. Recently, VPA exerts protective effects for various 
neurological diseases, including spinal cord injury [21,22], stroke [23], 
traumatic brain injury [24], motor neuron diseases [25], Parkinson’s 
disease [26], Alzheimer’s disease [27] and Huntington’s disease [28]. 
There is now accumulating evidence that VPA may have potential in 
the treatment of central nervous system disorders and the 
neuroprotective functions are linking with its inhibition on histone 
deacetylases (HDAC) [29,30]. It has recently been demonstrated that 
VPA robustly promotes neurite outgrowth, activates the extracellular 
signal regulated kinase pathway [30, 31,32]. However, the effect of 
VPA on the oxaliplatin-induced neuropathy remains unexplored. 
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Accordingly, in the present study, we investigated the effect of VPA 
in prevention of oxaliplatin induced periphery neuropathy in the rat 
model. The anti-neuropathic role of VPA was evaluated in oxaliplatin-
treated animals by analyzing pain behavior in relation to morphological 
and functional protection of the nervous system. 
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3. MATERIALS AND METHODS 
 
1) Animals 
Six-week-old male Sprague-Dawley rats weighing 200–250 g (Japan 
SLC, Shizuoka, Japan) were employed in the present study. Animals 
were housed in groups of three to four per cage (size 26 × 41 cm), fed 
a standard laboratory diet and tap water ad libitum, and kept at 25 ± 
2°C with a 12 h light/dark cycle, light at 8 a.m. All experiments were 
approved by the Experimental Animal Care and Use Committee of 
Tokyo Metropolitan University according to the National Institutes of 
Health guidelines (Permit Number: A28-16, A29-8), and we followed 
International Association for the Study of Pain (IASP) Committee for 
Research and Ethical Issues guidelines for animal research [33]. All 
efforts were made to minimize animal suffering and to reduce the 
number of animals used. 
2) Oxaliplatin model and pharmacological treatments 
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Oxaliplatin (Elplat®) was obtained from Yakult Co., Ltd. (Tokyo, 
Japan). VPA was purchased from Nippon Zoki Pharmaceutical Co. 
(Osaka, Japan). 
The rats (n=18) were divided into three groups (6 rats in each group) 
and treated as follows. Oxaliplatin group: oxaliplatin (4 mg/kg) was 
injected in intraperitoneal injection (i.p.) in volumes of 10 ml/kg twice 
weekly for 4 weeks (Days 1, 2, 8, 9, 15, 16, 22 and 23) (Fig. 1). 
Oxaliplatin was dissolved in a 5% glucose-water solution. The dose of 
oxaliplatin followed previous reports [6, 34]. Oxaliplatin + VPA group: 
administration both oxaliplatin (as above) and VPA (300 mg/kg) daily 
twice a day for 4 weeks in i.p. The dose of VPA followed previous 
reports [35, 36]. Control group: injection of vehicle (5% glucose 
solution) instead of oxaliplatin and VPA. 
3) Assessment of general toxicity 
The measurement of the body weights of rats was performed on Days 
0, 1, 2, 3, 8, 9, 10, 15, 16, 17, 22, 23, 24 and 28 in every groups, 
including on the day of treatment and immediately prior to sacrifice. 
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Rats were examined daily for abnormal clinical signs such as 
piloerection, hindlimb weakness, gait disturbance or gastrointestinal 
disorders such as diarrhea. 
4) von Frey test for mechanical allodynia 
The mechanical allodynia was assessed by von Frey test. The von 
Frey test was performed before the first drug administration (on Day 
0) and on Days 5, 15, 21 and 28 (Fig. 1). On Days 5, 15 and 21, the 
test was performed before drug administration. Rats were placed in a 
clear plastic box (20 × 17 × 13 cm) with a wire mesh floor and allowed 
to habituate for 30 min prior to testing. von Frey filaments (Aesthesio®, 
Precise Tactile Sensory Evaluator 20 pieces Kit with Carrying case, 
USA) ranging 1-15 g bending force were applied to the midplantar skin 
of each hind paw with each application held for 6 s. Fifty percent paw 
withdrawal thresholds were determined by a modification of up-down 
method that described by Kawashiri et al. [6] and Ushio et al. [37]. 
First, each hind paw was touched with some filaments from 1 g up to 
the force that rat exhibited the withdrawal response, in ascending order. 
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Next, the paw was touched with some filaments from 15 g down to the 
force that rat did not exhibit the response, in descending order. These 
up and down steps were repeated three times. Fifty percent thresholds 
were determined by average of the weakest force in each up or down 
step.  
5) Acetone test for cold hyperalgesia 
The cold hyperalgesia was assessed by acetone test. The acetone 
test was performed before the first drug administration and on the first 
day of drug administration (on Day 0 and Day 1) and on Days 5, 7, 14, 
21 and 28 (Fig. 1) according to the method described by Kawashiri et 
al. [6] and Ushio et al. [37]. On Days 1, 5, 7, 14 and 21, test was 
performed before drug administration. Rats were placed in a clear 
plastic box (20 × 17 × 13 cm) with a wire mesh floor and allowed to 
habituate for 30 min prior to testing. Fifty microlitre of acetone (Wako 
Pure Chemical Ltd., #016-00346, Osaka, Japan) was sprayed onto the 
plantar skin of each hind paw three times with a micro sprayer, and 
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rats were observed for 40 s from the start of the acetone spray. The 
number of elevation of each hind paw was recorded. 
6) Assay of sciatic nerve axonal degeneration 
On Day 28, the rats were deeply anesthetized with pentobarbital (50 
mg/kg), and transcardially perfused with phosphate-buffered saline 
(PBS) (0.1M, pH 7.4), followed by 2.5% (w/v) glutaraldehyde in PBS. 
The sciatic nerves were rapidly dissected, and the samples were kept 
overnight in the same fixative at 4 °C. The fixed fibers were post-fixed 
with 1% osmium tetroxide solution for 3 hours, dehydrated in a graded 
alcohol series, and embedded in EPON 815 (Wako, Japan). For light 
microscopy, semi-thin sections were cut from each block and stained 
with toluidine blue. The stained sections were observed using a light 
microscope (BX63, Olympus Corp., Tokyo, Japan). The density of axon 
area was calculated by image analysis software (ImageJ 1.50a; Wayne 
Rasband, National Institutes of Health, MD, USA).  
7) Histopathological assessment on dorsal root ganglia 
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On Day 28, the dorsal root ganglion (DRGs) and spinal cord 
specimens (at segments L4 and L5) were excised from rats of each 
group, and fixed by immersion in 4% PFA overnight at 4°C. The tissues 
were then washed with PBS, dehydrated with ascending grades of 
reagent alcohol, cleared in two changes of xylene, infiltrated with 
paraffin, and sliced to 5 μm, mounted on charged slides. The DRG 
specimens were stained with Azan-Mallory method as manual, and the 
spinal cord specimens were performed with immunohistochemistry for 
GFAP and Iba1 as below 2.8. 
Cellular dimensions of L4-L5 DRGs were measured using a method 
adapted from Di Cesare Mannelli et al. [3,38]. In these sections, using 
a 40x objective lens, the numbers of neurons with nuclei, nucleoli, 
multiple nucleoli, and nucleolar eccentricity (eccentric nucleolus) were 
counted. The nucleolus were considered eccentric when its center (or 
that of the largest one if there appeared to be more than one) lay in 
the outer half of the radius of the nucleus. The results were expressed 
as percentage of those cells with a visible nucleolus. Four consecutive 
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sections for each animal were analyzed. The reported data were 
obtained by averaging the data of L4 and L5 ganglia.  
8) Immunohistochemical evaluation of GFAP and Iba1 in L4-L5 
spinal cord 
The immunohistochemical procedures were performed according to 
our previous study [39]. Briefly, after rinsing the fixed tissue specimens 
in 0.01 M PBS (pH 7.4), endogenous peroxidase activity was inhibited 
by 30-min incubation in methanol containing 0.3% (v/v) hydrogen 
peroxide. After rinsing in PBS, the sections were blocked with normal 
goat serum for 1 h at room temperature, were then incubated for 
overnight at 4°C in PBS containing the primary antibodies, against glial 
fibrillary acidic protein (GFAP; mouse, 1:300; MAB3402, Chemicon, 
Temecula, USA) for astrocyte staining and Iba1 (rabbit, 1:200; #019-
19741, Wako Pure Chemicals, Osaka, Japan) for microglial staining. 
After rinsing in PBS, sections were incubated in donkey anti-mouse IgG 
secondary antibody labeled with Alexa Fluor 488 (1:2000, Thermo 
Fisher Scientific, Rockford, USA) and chicken anti-rabbit IgG secondary 
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antibody labeled with Alexa Fluor 488 (1:500, Thermo Fisher Scientific, 
Rockford, USA), respectively, at room temperature for 1 h. 
Negative control sections (no exposure to the primary antisera) were 
processed concurrently with the other sections for all 
immunohistochemical studies. We obtained a single optical density 
value for the dorsal horns by averaging the two sides in each rat, and 
these values were compared to the homologous average values from 
the vehicle-treated animals. 
9) Quantitative analyses of GFAP and Iba1 
immunohistochemistry 
Images were acquired by a motorized ZEISS ImagerM1 microscope 
equipped with a DS-Fi3 camera (Nikon, Tokyo, Japan). Morphological 
examination of astrocyte and microglia morphology was assessed by 
inspection of at least three fields (20 x) in the dorsal horn per section. 
Quantitative analysis of GFAP and Iba1-positive cells was performed 
by collecting at least three independent fields through a 20 X 0.5NA 
objective. The densities of GFAP and Iba1-positive cells were calculated 
  
17 
 
by means of the automatic thresholding and segmentation features of 
ImageJ (ImageJ 1.50a; Wayne Rasband, National Institutes of Health, 
MD, USA). Results, given as the area fraction (%) occupied by the 
thresholded GFAP- or Iba1-positive cell number, respectively. Five 
spinal cord sections were analyzed for each animal. 
10) Statistical analyses 
Data are expressed as the mean ± standard devtion (SD). ANOVA 
and the Tukey’s multiple comparison tests were employed for statistical 
analysis. All tests were performed as two-sided test and a p value of 
<0.05 was accepted as significant. 
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4. RESULTS   
 
1) General toxicity of oxaliplatin  
Rats were injected with either oxaliplatin (4 mg/kg) or VPA (300 
mg/kg) at dosages corresponding to human chemotherapy, while 5% 
glucose solution was used as a control treatment (Fig. 1). No 
deterioration in general status was observed in any of the groups, and 
no rats died in the course of our experiments. No significant differences 
in body weight were observed between groups at any time (data not 
shown). 
2) Effects of VPA on mechanical allodynia in oxaliplatin-
induced neuropathy 
Before the first oxaliplatin injection, there were no significant 
differences in withdrawal thresholds in all groups in the von Frey test. 
Oxaliplatin significantly reduced the withdrawal threshold compared 
with vehicle on Days 15, 21 and 28 (P < 0.01). Repeated 
administration of VPA significantly inhibited the oxaliplatin-induced 
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reduction of the withdrawal threshold on Days 21 and 28 (P < 0.05) 
(Fig. 2). 
3) Effects of VPA on cold hyperalgesia in oxaliplatin-induced 
neuropathy 
In the acetone test, there were no significant differences in number 
of withdrawal responses in all groups before the first oxaliplatin 
injection. Oxaliplatin significantly increased the number of withdrawal 
responses compared with vehicle on Days 1, 5, 7 and 14 (P < 0.05 or 
0.01). However, no significant difference in withdrawal responses 
compared to the vehicle group was observed on Days 21 and 28 (P > 
0.05). Repeated administration of VPA did not significantly inhibited the 
oxaliplatin-induced increase of the number of withdrawal responses on 
any days (P > 0.05) (Fig. 3). 
4) Effect of VPA on oxaliplatin-induced histological change in 
rat sciatic nerve 
Histological abnormalities in sciatic nerve were observed in vehicle-, 
oxaliplatin-treated and oxaliplatin + VPA-treated rats on Day 28. The 
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quantification analysis showed that oxaliplatin caused the decrease in 
the density of myelinated fibers and the degeneration of myelinated 
fibers in rat sciatic nerve (P < 0.05, Fig. 4B), and co-treatment with 
VPA had no effect on the oxaliplatin-induced decrease of the density of 
myelinated fibers (P > 0.05, Fig. 4C). 
5) Effect of VPA on morphological derangement of DRG 
neurons 
Morphologic and morphometric determinations on morphological 
derangement of DRG neurons were performed under the light 
microscope after Azan–Mallory stain. On day 28, oxaliplatin-induced 
damage was evidenced by the occurrence of multinucleolated neurons 
(Fig. 5B) and nucleolar eccentricity (Fig. 5B and C) distributed on small, 
medium and large neurons. VPA exerted a significant protective effect 
by reducing the occurrence of eccentric nucleolus neurons caused by 
oxaliplatin (Fig. 5D).  
6) Effect of VPA treatment on glial cell activation profile in the 
spinal cord 
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To establish a relationship between pain relief and glial modulation 
the cell densities of astrocytes and microglia were calculated in the 
dorsal horn of the spinal cord using immunohistochemistry with 
antibodies against GFAP and Iba1, respectively.  
In the spinal cord, repeated oxaliplatin injections (Day 28) induced 
an increase in GFAP-positive cells (Fig. 6B), astrocyte density increased 
over the entire surface of the spinal cord, particularly in the superficial 
laminae. VPA treatment prevented the increase in the density of the 
dorsal horn GFAP-positive cells (Fig. 6C). 
The same as GFAP and shown in Fig. 7B, the number of Iba1-
expressing cells in dorsal horn superficial laminae of oxaliplatin-treated 
rats was significantly increase than the vehicle group. VPA treatment 
prevented the increase in the density of the dorsal horn microglial cells 
(Fig. 7C).  
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5. DISCUSSION  
 
In the present study, to demonstrate that VPA-treatment relieved the 
oxaliplatin-induced peripheral neuropathy, according to previous 
studies [10,12], oxaliplatin (4 mg/kg) was injected intraperitoneally to 
rats twice a week, and VPA (300 mg/kg) was administered daily twice 
a day for 4 weeks. The results were analysed using behavioral tests, 
and histopathological or immunohistochemical evaluations. In the von 
Frey test, VPA administration significantly attenuated the mechanical 
hyperalgesia induced by oxaliplatin injection. On the other hand, it was 
almost ineffective against the oxaliplatin-induced cold hyperalgesia in 
the acetone test. Therefore, it suggested that VPA has a protective 
effect on oxaliplatin-induced chronic peripheral neuropathy on the 
mechanical hyperalgesia.  
VPA as a broad-spectrum HDAC inhibitor, is an anticonvulsant and 
mood-stabilizing drug with neuroprotective effects [40]. The HDAC 
inhibitors, such as trichostatin A and valproic acid, restored peripheral 
and systemic morphine analgesia in neuropathic pain. It suggests that 
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HDAC inhibitors could serve as adjuvant analgesics to morphine for the 
management of neuropathic pain [35]. A clinical investigation 
demonstrated sodium valproate is well-tolerated, and provides 
significant subjective improvement in painful diabetic neuropathy [41]. 
Oxaliplatin-induced peripheral neurotoxicity in the peripheral nerve 
shows several histological characteristics including demyelination and 
degeneration of nerve fibers, and decrease in the number of myelinated 
fibers [42]. In this study, oxaliplatin caused sciatic nerves of the 
oxaliplatin-treated group showed axonal degeneration and decreased 
density of myelinated fibers. However, these histological changes were 
not ameliorated in the tissue of rats treated with co-administration of 
oxaliplatin and VPA. It suggested that VPA was unable to prevent 
demyelination and degeneration of nerve fibers from oxaliplatin-
induced peripheral neurotoxicity. 
Oxaliplatin causes damage to cell bodies and selective atrophy of 
subpopulations of DRG neurons [43]. In previous evidence [44], it is 
demonstrated that DRGs are a primary target for oxaliplatin 
neurotoxicity. In the present study, the histological determinations 
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were performed on lumbar DRGs from oxaliplatin-treated rats, VPA 
exerted a significant protective effect by reducing the occurrence of 
multinucleolated neurons and the nucleolar eccentricity caused by 
oxaliplatin. VPA prevented morphological derangements in DRGs from 
oxaliplatin-treated rats, showed the same effects of N-
Palmitoylethanolamine in oxaliplatin-treated rats[3]. 
Besides the neuronal damage, glial cells have recently been 
recognized as a powerful modulator of pain. The activation of spinal 
astrocytes has been reported to be involved in the oxaliplatin-induced 
neuropathic pain [45,46]. In models of trauma-induced neuropathy, 
microglia appear to exert a key role in the initial phases of neuropathic 
pain whereas astrocytes may be involved in its maintenance [47,48]. 
In addition, glial inhibitors have been described as pain relievers and 
glial cells are emerging as a new target for drug development [49]. The 
increased cell density of astrocyte and microglia is strongly related to 
pain hypersensitivity since the glial inhibitor minocycline and 
fluorocitrate fully prevent oxaliplatin-evoked pain [38]. 
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N-Palmitoylethanolamine has been reported to modulate glial cells 
and exert antinociceptive effects on oxaliplatin-induced neuropathic 
pain in rats [3]. Furthermore, Kimura et al. [50,51] reported VPA 
(300mg/kg) was administered via intraperitoneal injection in a 
conditional knockout mice, which exhibit glaucomatous pathology 
including glutamate neurotoxicity and oxidative stress in the retina, 
daily for 2 weeks. It showed VPA prevents retinal degeneration in a 
murine model of normal tension glaucoma. Subcutaneous injections of 
300 mg/kg VPA twice a day, VPA-mediated neuroprotection against I/R 
injury in the retina may involve cytoprotective Hsp70 induction via 
transcriptional activation and inhibition of the mitochondria-mediated 
apoptosis pathway [40]. In developing brain, few studies have 
examined VPA effects on glial cells, particularly astrocytes [36]. 
In the present study, to examine the effect of VPA on oxaliplatin-
induced glial activation on spinal cord, immunohistochemical 
evaluation using GFAP and Iba1 antibodies was performed. On day 28, 
a lower pain threshold was accompanied by effects on spinal astrocytes 
and microglia that involve a significant increase of the number of cells 
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immunoreactive to GFAP and Iba1, respectively. The present results 
reveal an inhibitory effect of VPA on astrocytes and microglia in the 
dorsal horn of the spinal cord with decreasing in the number or 
activation of both cell types. It suggested that VPA-ameliorated 
oxaliplatin-induced astrocytes and microglia activation, meaning that 
proinflammatory mediator-related nociceptor sensitization could be 
prevented by VPA administration.  
In conclusion, the present results demonstrate for the first time that 
VPA administration ameliorated the oxaliplatin-induced behavioral, 
biochemical and histopathological changes in rats. The VPA-mediated 
effects in this study may be attributed to neuroprotection properties 
and ameliorating oxaliplatin-induced astrocytes and microglial 
activation. VPA may offer a dual protective approach against etiological 
factors and resulting maladaptative plasticity. However, further study 
is needed to evaluate the effect of VPA on several symptoms of 
oxaliplatin-induced peripheral neuropathy and the mechanism of VPA 
on biomolecular changes of oxaliplatin-induced neuropathy. To get 
more conclusive results, a larger number of rats in each group and 
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more elaborate techniques are needed.  
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7. FIGURES AND LEGENDS 
 
 
 
 
 
Figure 1. Schedual of drug administration and behavioral test.  
A: Acetone test; V: von Frey test; vehicle: intraperitoneal injection 
(i.p.) with 5% glucose solution; oxaliplatin: oxaliplatin 4mg/kg i.p.; 
oxaliplatin + VPA group: oxaliplatin 4mg/kg and VPA 300mg/kg i.p., 
respectively. 
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Figure 2. Effects of repeated administration of VPA on 
oxaliplatin-induced mechanical allodynia in von Frey test in 
rats.  
Oxaliplatin (4 mg/kg) was administered i.p. twice a week for 4 weeks. 
VPA (300 mg/kg) was administered daily twice a day for 4 weeks. 
The von Frey test was performed before the first drug administration 
(on day 0) and on days 5, 15, 21 and 28. Values were expressed as 
the mean ± standard error mean of 6 animals. ∗∗P < 0.01 compared 
with vehicle. ∗P < 0.05 compared with oxaliplatin alone. 
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Figure 3. Effects of repeated administration of VPA on 
oxaliplatin-induced cold hyperalgesia in acetone test in rats.  
Oxaliplatin (4 mg/kg) was administered i.p. twice a week for 4 weeks. 
VPA (300 mg/kg) was administered daily twice a day for 4 weeks. 
The acetone test was performed before the first drug administration 
(on day 0) and on days 1, 3, 5, 7, 14, 21 and 28. Values are 
expressed as the mean ± standard error mean of 6 animals. ∗P < 
0.05, ∗∗P < 0.01 compared with vehicle.  
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Figure 4. Effect of repeated administration of VPA on 
histological change induced by oxaliplatin (B) in rat sciatic 
nerve.  
On day 28, The sciatic nerve was harvested, and samples were 
stained with toluidine blue. Images were captured at 800× 
magnification. The area of axon was calculated by image analysis 
software (ImageJ 1.50a). Values were expressed as the mean ± 
standard error mean of six animals. *P < 0.05 compared with vehicle 
(A). (C), oxiliplatin + VPA. 
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Figure 5. Morphological aspects of the peripheral nervous 
system. The protective effect of repeated administrations of VPA was 
evaluated on oxaliplatin-damaged DRGs on day 28. DRG sections 
were stained by the Azan-Mallory method. Light micrographs (original 
magnification 200 x) were analyzed by counting the incidence of 
eccentric nucleoli (#) and multinucleolated neurons (*).  
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Figure 6. Astrocytes activation profile in the lumbar 4-5 spinal 
cord.  
The effect of repeated treatment with VPA was evaluated in 
oxaliplatin-treated rats on day 28. The density of GFAP-positive cells 
was calculated by means of the automatic thresholding and 
segmentation features of ImageJ (ImageJ 1.50a; Wayne Rasband, 
National Institutes of Health, MD, USA) in (D). Images (original 
magnification 200 x) of sections showed vehicle in (A), oxaliplatin in 
(B) and oxaliplatin + VPA in (C). Each value represents the mean of 6 
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rats per group, performed in two different experimental sets. 
*P<0.05 versus vehicle; #P<0.05 versus oxaliplatin. 
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Figure 7. Microglia activation profile in the lumbar 4-5 spinal 
cord.  
The effect of repeated treatment with VPA was evaluated in 
oxaliplatin-treated rats on day 28. The density of Iba1-positive cells 
was calculated by means of the automatic thresholding and 
segmentation features of ImageJ (ImageJ 1.50a; Wayne Rasband, 
National Institutes of Health, MD, USA) in (D). Images (original 
magnification 200 x) of sections showed vehicle in (A), oxaliplatin in 
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(B) and oxaliplatin + VPA in (C). Each value represents the mean of 6 
rats per group, performed in two different experimental sets. 
*P<0.05 versus vehicle; #P<0.05 versus oxaliplatin. 
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